-
| ISIN | None |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 10.5 |
|---|---|
| Beta | 0.24 |
| Market Cap | 36M |
| PE Ratio | None |
| Dividend Yield | None |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for the treatment of presbyopia and dim light or night vision disturbances; APX3330, a small-molecule inhibitor of Ref-1 that has completed Phase II clinical trial for the treatment of diabetic retinopathy; andOPGx-LCA5, an early-onset retinal degeneration which is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; OPGx-BEST1, developed for bestrophin-1 (BEST1)-related inherited retinal diseases or bestrophinopathies. Its other pre-clinical IRD pipeline, including OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-GNGB. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IRD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025